Author

the SOBERANA Phase 3 team

OpenAlex ID: A5157836839

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

2022 · María Eugenia Toledo-Romaní, Mayra García-Carmenate, et al. · The Lancet Regional Health - Americas · 61

Works count: 1

Citation count: 61

H-index: 1

I10-index: 1